

Blockade of IL-33 release, and suppression of type 2 innate lymphoid cell responses, by helminth secreted products in airway allergy

Henry J McSorley *et al.*

Supplementary Material

Supplementary Figure 1

Complete cell profile of BAL (some data are also in Figure 1). Supp Figure 1: Bronchoalveolar lavage cells (A) and lung tissue cells (B) were treated with *Alternaria*, OVA and HES as described in Figure 1. Numbers of eosinophils (SiglecF+CD11c-), Neutrophils (CD11b+GR1+), alveolar macrophages (CD11c+SiglecF+) and Thelper cells (CD4+) were then assessed by flow cytometry. *** = $p < 0.001$, ** = $p < 0.01$, * = $p < 0.05$, when Alt-OVA-HES:OVA groups was compared to Alt-OVA:OVA group. ### = $p < 0.001$, ## = $p < 0.01$, # = $p < 0.05$, when Alt-OVA:OVA groups was compared to Alt-OVA:PBS group.

Supplementary Figure 2

Gating strategy for type II Innate Lymphoid Cells (ILC2), and representative plots of IL-4, IL-5 and IL-13 staining on ILC2s after 4 h PMA/Ionomycin/BrefeldinA stimulation.

Supplementary Figure 3

DO11.10 cells were transferred, and the *Alternaria*/OVA model carried out as described in Fig. 2 H-J. Absolute numbers of lymph node (LN) (A) and lung (C), or proportions of lung (B) IL-4+CD4+KJ126+ were calculated.

Supplementary Figure 4

Absolute lung eosinophil cell numbers were calculated from mice deficient in RAG (A), IL-17RB (B), IL-17RBxST2 (C), MyD88xTRIF (D) or TLR4 (E) or wild-type controls shown in Fig. 3.

Supplementary Figure 5



Representative staining for CD44 and CD25 in IL-13-GFP+Lineage- cells after treatment with *Alternaria* +/- HES, as described in **Fig. 4 B**.

Supplementary Figure 6



48 h after *Alternaria* administration with or without HES to C57BL/6 wild-type or RAG-deficient mice, cell-free BAL fluid was tested for levels of IL-5 (**A**), RELM α (**B**) and Ym1 (**C**). Significance compares *Alternaria* level to *Alternaria* + HES level.


Supplementary Figure 7

Gating strategy and representative plots for IL-33-Citrine mice treated with *Alternaria*, OVA and HES as described in **Fig. 5 G**.



McSorley et al., Supplementary Figure 2





McSorley et al.,
Supplementary
Figure 4

